Inclusion Criteria:  Male or female age 18 years or older, with documented full, written informed consent Requiring cardiothoracic (CT) surgery with cardiopulmonary bypass (CPB) within 30 hours from last dose of either apixaban or rivaroxaban (*note that patients must be taking apixaban or rivaroxaban for one of the following indications: a) reduction of stroke/systemic embolism in nonvalvular atrial fibrillation, or b) initial or extended treatment of venous thromboembolism)  Exclusion Criteria:  >30hrs between last apixaban or rivaroxaban dose and start of CT surgery Patients on low dose apixaban or rivaroxaban for prophylactic indications Heart-lung transplant procedures Procedures for ventricular assist device  Any of the below conditions that pose a known risk for increased bleeding  Heparin induced thrombocytopenia Preoperative platelet count <50,000u/L Hemophelia INR greater than or equal to 1.8 Prohibited concomitant antithrombotic medications as defined in the study protocol Acute sickle cell crisis Known allergy to device components Active (untreated) systemic infection History of major organ transplantation and those currently receiving immunosuppressive medication or who are profoundly immune suppressed Women with positive pregnancy test during current admission or who are breast-feeding Life expectancy <30 days Inability to comply with requirements of the study protocol Treatment with investigational drug or device within 30 days of current surgery Previous enrollment in this trial